- In November 2023, Abbott’s SyncAV Plus CRT technology achieved the narrowest QRS complex for improved heart failure treatment. This technology optimized pacing to significantly reduce QRS duration, offering enhanced synchronization of the heart's ventricles. The key benefit of SyncAV Plus was its ability to provide better clinical outcomes, including improved heart function and reduced hospitalizations for heart failure patients. Studies showed that 100% of patients experienced the narrowest QRS with this technology, underscoring its effectiveness in improving the response to cardiac resynchronization therapy. This advancement enhanced the quality of life for patients with left bundle branch block and other heart failure symptoms
- In March 2021, a new analysis of the REVERSE Trial by Medtronic highlighted the benefits of Cardiac Resynchronization Therapy (CRT) for a broader range of heart failure patients. This analysis revealed that CRT offered significant improvements in heart function and quality of life, especially for patients with mild symptoms. The key benefit of this treatment approach was its potential to delay disease progression, reduce hospitalizations, and improve patient outcomes. Medtronic's ongoing research underscored the importance of CRT in managing heart failure, emphasizing its effectiveness for more individuals, not just those with severe conditions
